Influenza, Human
Conditions
Keywords
exercise, vaccine, older adults
Brief summary
This study evaluates whether resistance exercise will improve immune responses to the seasonal influenza vaccine in older adults. One third of the participants will perform exercise in the arm that receives the vaccine, one third of the participants will perform the same exercise in the arm that does not receive the vaccine, and one third will only receive the vaccine.
Detailed description
Resistance exercise, particularly novel eccentric exercise, recruits immune cells to the targeted muscle. The exercises selected here targets the deltoid and biceps brachii muscles-those same muscles that the flu vaccine is delivered to during typical vaccination.
Interventions
BEHAVIORALExercise
10 sets of 5 repetitions of 80% of calculated one-repetition maximum weight of lateral side arm raise and biceps curls, alternating
Sponsors
National Institute on Aging (NIA)
University of Houston
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* non-frail older adult (≥65 years old) of any sex and race/ethnicity * non-smokers (\>10 yrs) * meets American College of Sports Medicine criteria for participation in exercise * US resident
Exclusion criteria
* underlying medical problems that contraindicate supervised resistance exercise * past or present history of autoimmune disease, HIV, hepatitis, stroke, or cardiovascular disease * current debilitating arthritis of the shoulder * central or peripheral nervous disorders * bedridden in the past three months * history of vaccine-related allergies, or severe egg allergy; * physician-confirmed influenza infection in the prior year * regular user of corticosteroids * functional or cognitive impairment that would limit exercise performance or prohibit informed consent * blood pressure greater than 160/90 * participation in resistance arm exercises in the prior 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cell mediated immunity change at 6 weeks post-vaccine | baseline and 6 weeks | The change in the peripheral blood mononuclear cell response to overnight ex vivo culture with the seasonal quadrivalent vaccine detected via Interferon-gamma ELISPOT will be calculated from baseline at 6 weeks post-vaccine |
| Antibody titer change at 6 weeks post-vaccine | baseline and 6 weeks | The change in influenza-specific antibody titers in serum measured by hemagglutination inhibition assay will be calculated from baseline at 6 weeks post-vaccine |
| Cell mediated immunity change at 6 months post-vaccine | baseline and 6 months | The change in the peripheral blood mononuclear cell response to overnight ex vivo culture with the seasonal quadrivalent vaccine detected via Interferon-gamma ELISPOT will be calculated from baseline at 6 months post-vaccine |
| Antibody titer change at 6 months post-vaccine | baseline and 6 months | The change in influenza-specific antibody titers in serum measured by hemagglutination inhibition assay will be calculated from baseline at 6 months post-vaccine |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Muscle soreness | 7 days | Self-reported pain in upper arm shoulder/ region of both arms collected once daily for 7 days after vaccination. Item will be scored 0-10 (0= no pain; 10= worst possible pain). |
| Influenza-like symptoms | Measured monthly for six months | Self-report symptoms of influenza infection, guided by an influenza self-screening questionnaire( modified from University of California Davis Student Health and Counseling Service influenza self-screening questionnaire) |
Countries
United States
Outcome results
None listed